{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-005393","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2024-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.147372+00:00","generated_at":"2026-05-31T01:01:31.789750+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioCryst awarded up to $69M HHS contract for RAPIVAB supply to Strategic National Stockpile","bullets":["Contract covers up to 95,625 doses of RAPIVAB over five years for influenza treatment.","First ordering period executed at $13.9M for 19,125 doses to be supplied by Sept 2025.","Awarded by HHS ASPR; four optional 12-month ordering periods remain.","Prior CDC contract of $34.7M for up to 50,000 doses concluded in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-005393","json":"https://secwatch.observer/filing/0001171843-24-005393.json","markdown":"https://secwatch.observer/filing/0001171843-24-005393.md","text":"https://secwatch.observer/filing/0001171843-24-005393.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184324005393/0001171843-24-005393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184324005393/f8k_093024.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:01:31.789750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}